Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

UPS Q2 revenues beat estimates, earnings disappoint

(Sharecast News) - Logistics firm UPS posted Q2 revenues that came in ahead of Wall Street estimates on Tuesday, but said earnings per share had fallen short of expectations. UPS reported Q225 revenues of $21.2bn, slightly ahead of estimates of $21.2bn, while adjusted earnings per share of $1.55 were just shy of the $1.57 per share expected on the Street. Operating profits were $1.9bn on a non-GAAP basis, reflecting ongoing cost pressures and transformation charges.

The Kentucky-based group said its US domestic segment saw a slight revenue dip of 0.8% due to lower volume, while international revenues grew 2.6% on stronger daily volume. Supply chain solutions revenues dropped 18.3%, hit by UPS' divestiture of Coyote.

UPS reaffirmed its FY cost savings target of $3.5bn through network reconfiguration and its "Efficiency Reimagined" program, noting that it plans to spend $3.5bn in capex.

UPS also opted not to provide any updated revenue or profit guidance, citing ongoing macroeconomic uncertainty.

As of 1425 BST, UPS shares were down 2.79% in pre-market trading at $98.75 each.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.